Comparative Benchmarking
In the context of the broader market, PHAR competes directly with industry leaders such as ESPR and ZVRA. With a market capitalization of $942.14M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against ESPR's 56.84% and ZVRA's 213.48%. Such benchmarking helps identify whether Pharming Group NV is trading at a premium or discount relative to its financial performance.
